Goefibro-M 25 Tablet
Product Info
| Prescription required | Yes |
| Marketer | Koye Pharmaceuticals Pvt ltd |
| Active Ingredient | Mifepristone (25mg) |
| Storage | Store below 30°C |
| Chemical Class | Oxosteroid |
| Habit Forming | No |
| Therapeutic Class | GYNAECOLOGICAL |
| Action Class | Anti-progesterone |
| User Rating | 4.8 |
| User Reviews | 654 |
FAQ
What is Goefibro-M 25 and what it is used for?
Goefibro-M 25 contains a medicine called Mifepristone. It helps in medical termination of the pregnancy. It works by blocking the effect of progesterone (a female sex hormone) which is required for maintenance of pregnancy. It is only used to terminate a pregnancy which should not be more than 63 days old, counting from the first day of the last menstrual period.
What should I expect after taking Goefibro-M 25?
You may or may not experience vaginal bleeding or spotting after taking this medicine. After 48 hours of taking Goefibro-M 25, your doctor shall examine you and may prescribe you another medicine (Misoprostol) for complete termination of pregnancy. After 14 days of taking Goefibro-M 25, your gynaecologist may run some blood tests or perform ultrasonography to confirm whether the pregnancy has been terminated or not.
How and in what dose should I use Goefibro-M 25?
Goefibro-M 25 can be taken orally with a glass of water. It should be taken under the supervision of a doctor.
Can Goefibro-M 25 affect my future chances of getting pregnant?
No, studies have shown that this medicine does not impair the fertility of the women. Your future chances of getting pregnant are as equal as of those who have not taken this medicine.
What are the common side effects of taking Goefibro-M 25?
Vaginal bleeding and abdominal cramping are the most common side effects of using Goefibro-M 25. The other common side effects include diarrhea, nausea, and vomiting. If you experience a very heavy vaginal bleeding or if any of these side effects bother you please consult with your gynaecologist.
What if you forget to take Goefibro-M Tablet?
If you miss a dose of Goefibro-M 25, please consult your doctor.\n
Goefibro-M 25 Tablet Reviews
Goefibro-M 25 is an anti-progestational steroid class of drug used for medical termination of pregnancy. It works by blocking the action of progesterone, an essential hormone for the development of pregnancy.
Goefibro-M 25 is given alone or in combination with some other medicine to attain the maximum benefit. It should be taken with food or as your doctor's advice. It should be taken orally, by swallow the tablets whole with a glass of water. If you experience vomiting within 45 minutes of tablet intake, inform your doctor or take another tablet. The medicine may take 24- 48 hours to show its action and you experience bleeding.
The most common side effects of this medicine include nausea, vomiting, uterine cramps, diarrhea, infection following abortion, and uterine bleeding. If these bother you or appear serious, let your doctor know. There may be ways of reducing or preventing them. If you experience heavy vaginal bleeding or abdominal pain on taking this medicine, you should inform your doctor immediately.
Before taking this medicine, tell your doctor if you have ever had an ectopic pregnancy, or you are breastfeeding or using an intrauterine device. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works. You must avoid strenuous activity like heavy exercise, running, and driving while abortion as it can affect the bleeding. Your doctor may perform an ultrasound or pelvic examination to check for abortion completion.
Goefibro-M 25 is given alone or in combination with some other medicine to attain the maximum benefit. It should be taken with food or as your doctor's advice. It should be taken orally, by swallow the tablets whole with a glass of water. If you experience vomiting within 45 minutes of tablet intake, inform your doctor or take another tablet. The medicine may take 24- 48 hours to show its action and you experience bleeding.
The most common side effects of this medicine include nausea, vomiting, uterine cramps, diarrhea, infection following abortion, and uterine bleeding. If these bother you or appear serious, let your doctor know. There may be ways of reducing or preventing them. If you experience heavy vaginal bleeding or abdominal pain on taking this medicine, you should inform your doctor immediately.
Before taking this medicine, tell your doctor if you have ever had an ectopic pregnancy, or you are breastfeeding or using an intrauterine device. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works. You must avoid strenuous activity like heavy exercise, running, and driving while abortion as it can affect the bleeding. Your doctor may perform an ultrasound or pelvic examination to check for abortion completion.
How Goefibro-M 25 Tablet Works
Goefibro-M 25 blocks the effects of progesterone, a natural female hormone which is needed for the pregnancy to sustain. Without this hormone, the lining of the uterus (womb) breaks down as it does during a menstrual period and stops the growth of the pregnancy.
How to Use Goefibro-M 25 Tablet
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Goefibro-M 25 is to be taken with food.
Benefits of Goefibro-M 25 Tablet
- In Medical abortion: Goefibro-M 25 is used to cause an abortion during the early part of a pregnancy. It is used up to week 10 of pregnancy (up to 70 days after the first day of your last menstrual period). This medicine effectively blocks the natural female hormone, called progesterone, that is needed for your pregnancy to continue. Please use it only as advised by the doctor.
Uses of Goefibro-M 25 Tablet
- Medical abortion
Goefibro-M 25 Tablet Side Effects
Safety Tips
Kidney
CONSULT YOUR DOCTOR
There is limited information available on the use of Goefibro-M 25 in patients with kidney disease. Please consult your doctor.
Alcohol
UNSAFE
It is unsafe to consume alcohol with Goefibro-M 25.
Liver
CONSULT YOUR DOCTOR
There is limited information available on the use of Goefibro-M 25 in patients with liver disease. Please consult your doctor.
Breast feeding
CONSULT YOUR DOCTOR
Goefibro-M 25 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Driving
UNSAFE
Goefibro-M 25 may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Pregnancy
UNSAFE
Goefibro-M 25 is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Quick Tips
- It does not affect fertility. Use contraception to avoid pregnancy.
- Be cautious while driving or doing anything that requires concentration as it can cause dizziness and sleepiness.
- Take it no later than 63 days after the first day of your last menstrual period.
- Vaginal bleeding may or may not occur after taking this medicine. Inform your doctor immediately if excessive bleeding occurs or if you suffer from severe abdominal pain.
- Goefibro-M 25 helps in medical termination of pregnancy.
- If you vomit within 45 minutes of taking the tablet, talk to your doctor immediately. You will need to take another tablet.
- Take it only as prescribed by the doctor. Miscarriages, if incomplete, may result in serious medical complications leading to hospitalization, surgery and possible infertility.
References
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 916-19.
- Masters SB. Hypothalmic & Pituitary Hormones. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 716-17.
- Drugs.com. Mifepristone.
- Central Drugs Standard Control Organisation (CDSCO).
- Mifepristone. Menlo Park, California: Corcept Therapeutics Incorporated; 2000.
- Levin ER, Hammes SR. Estrogens and Progestins. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1184-85.